Agilent Technologies, Inc. Expected to Earn Q1 2023 Earnings of $1.31 Per Share (NYSE:A)

Agilent Technologies, Inc. (NYSE:AGet Rating) – Equities researchers at Jefferies Financial Group cut their Q1 2023 earnings per share (EPS) estimates for Agilent Technologies in a report issued on Tuesday, November 22nd. Jefferies Financial Group analyst B. Couillard now forecasts that the medical research company will post earnings of $1.31 per share for the quarter, down from their prior forecast of $1.37. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.64 per share. Jefferies Financial Group also issued estimates for Agilent Technologies’ Q2 2023 earnings at $1.22 EPS.

A number of other equities analysts have also weighed in on A. Evercore ISI boosted their price objective on Agilent Technologies from $140.00 to $155.00 in a research note on Tuesday. StockNews.com began coverage on Agilent Technologies in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. KeyCorp boosted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Tuesday. Bank of America upped their price target on Agilent Technologies from $148.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, August 17th. Finally, Cowen upped their price target on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and an average price target of $157.00.

Agilent Technologies Stock Performance

NYSE A opened at $155.35 on Thursday. The stock’s fifty day moving average is $133.99 and its two-hundred day moving average is $128.48. The firm has a market capitalization of $45.99 billion, a P/E ratio of 37.25, a price-to-earnings-growth ratio of 2.78 and a beta of 1.06. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.41 and a current ratio of 2.03. Agilent Technologies has a fifty-two week low of $112.52 and a fifty-two week high of $162.62.

Agilent Technologies (NYSE:AGet Rating) last issued its quarterly earnings results on Monday, November 21st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.14. The firm had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.76 billion. Agilent Technologies had a return on equity of 30.31% and a net margin of 18.31%. The business’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 earnings per share.

Agilent Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 25th. Investors of record on Tuesday, January 3rd will be issued a $0.225 dividend. This represents a $0.90 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Friday, December 30th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.21. Agilent Technologies’s payout ratio is currently 20.14%.

Insider Activity at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 128,726 shares of the business’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $155.73, for a total value of $20,046,499.98. Following the sale, the chief executive officer now owns 260,691 shares in the company, valued at approximately $40,597,409.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Agilent Technologies news, CEO Michael R. Mcmullen sold 6,775 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $130.11, for a total transaction of $881,495.25. Following the sale, the chief executive officer now owns 191,358 shares in the company, valued at approximately $24,897,589.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 128,726 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $155.73, for a total value of $20,046,499.98. Following the sale, the chief executive officer now owns 260,691 shares in the company, valued at approximately $40,597,409.43. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,326 shares of company stock worth $26,474,537.

Institutional Investors Weigh In On Agilent Technologies

Several large investors have recently bought and sold shares of the stock. Toroso Investments LLC increased its holdings in Agilent Technologies by 9.6% during the 3rd quarter. Toroso Investments LLC now owns 6,568 shares of the medical research company’s stock worth $797,000 after purchasing an additional 577 shares during the period. CVA Family Office LLC increased its holdings in Agilent Technologies by 722.2% during the 3rd quarter. CVA Family Office LLC now owns 370 shares of the medical research company’s stock worth $45,000 after purchasing an additional 325 shares during the period. IHT Wealth Management LLC purchased a new stake in Agilent Technologies during the 3rd quarter worth about $359,000. B. Riley Wealth Advisors Inc. boosted its position in shares of Agilent Technologies by 5.8% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 5,086 shares of the medical research company’s stock worth $619,000 after acquiring an additional 278 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Agilent Technologies during the 3rd quarter worth about $3,401,000.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Read More

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.